Study:
A Phase II Study of Bevacizumab Plus Docetaxel and Gemcitabine in Subjects With Advanced, Previously Untreated, Non-Squamous Non-Small Cell Lung Cancer
Rationale:
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such
as docetaxel and gemcitabine hydrochloride, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Giving
bevacizumab together with docetaxel and gemcitabine hydrochloride may kill more tumor cells.
Purpose:
This phase II trial is studying how well giving bevacizumab together with docetaxel
and gemcitabine hydrochloride works in treating patients with stage IIIB, stage IV, or
recurrent non-small cell lung cancer.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Lung Cancer |
Biological: bevacizumab
Drug: docetaxel
Drug: gemcitabine hydrochloride |
Phase 2 |
Verified by
Nathan Pennell, MD, PhD
February, 2013
Sponsored by: Nathan Pennell, MD, PhD
Information provided by: Case Comprehensive Cancer Center
ClinicalTrials.gov identifier: NCT00970684
Study Type: Interventional
Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio 44195
United States
Hillcrest Hospital, a Cleveland Clinic Hospital
Mayfield Heights, Ohio 44124
United States
Nathan Pennell, MD, PhD., Principal Investigator
Afshin Dowlati, MD., Principal Investigator